HIV-1 cell entry and advances in viral entry inhibitor therapy

被引:52
作者
Cooley, LA
Lewin, SR [1 ]
机构
[1] Royal Melbourne Hosp, Victorian Infect Dis Serv, Parkville, Vic 3050, Australia
[2] Royal Melbourne Hosp, Victorian Infect Dis Reference Lab, Parkville, Vic 3050, Australia
[3] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia
关键词
HIV-1 cell entry; HIV-1 entry inhibitor; HIV-1 fusion inhibitor; antiretroviral therapy;
D O I
10.1016/S1386-6532(02)00111-7
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Despite the considerable successes of highly active antiretroviral therapy, new classes of therapeutic agents are still urgently needed. Unfortunately, the emergence of antiviral resistance and drug toxicity remain challenging obstacles to successful treatment in many HIV-1-infected individuals. HIV-1 entry is a multi-step process that is an attractive target for the development of new classes of therapeutic agents. Considerable progress has been made in the understanding of HIV-1 cell entry, enabling the design of specific agents that can inhibit each step of cellular entry. A number of promising agents have commenced clinical trials, including the attachment inhibitor PRO 542, co-receptor inhibitor AMD3100 and fusion inhibitor T-20. A greater number of HIV-1 entry inhibitors are in preclinical development. This review outlines the mechanisms involved in HIV-1 entry and the sites,of action of specific HIV-1 inhibitors. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:121 / 132
页数:12
相关论文
共 47 条
  • [21] Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
    Kilby, JM
    Hopkins, S
    Venetta, TM
    DiMassimo, B
    Cloud, GA
    Lee, JY
    Alldredge, L
    Hunter, E
    Lambert, D
    Bolognesi, D
    Mathews, T
    Johnson, MR
    Nowak, MA
    Shaw, GM
    Saag, MS
    [J]. NATURE MEDICINE, 1998, 4 (11) : 1302 - 1307
  • [22] LALEZARI J, 2001, 8 C RETR OPP INF CHI
  • [23] LALEZARI J, 1999, 39 INT C ANT AG CHEM
  • [24] LEONARD CK, 1990, J BIOL CHEM, V265, P10373
  • [25] A TRIMERIC STRUCTURAL DOMAIN OF THE HIV-1 TRANSMEMBRANE GLYCOPROTEIN
    LU, M
    BLACKLOW, SC
    KIM, PS
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (12): : 1075 - 1082
  • [26] Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
    Mosier, DE
    Picchio, GR
    Gulizia, RJ
    Sabbe, R
    Poignard, P
    Picard, L
    Offord, RE
    Thompson, DA
    Wilken, J
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (05) : 3544 - 3550
  • [27] Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion
    Nagashima, KA
    Thompson, DAD
    Rosenfield, SI
    Maddon, PJ
    Dragic, T
    Olson, WC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (07) : 1121 - 1125
  • [28] OBRIEN W, 2001, HIV ENTRY MOL INSIGH
  • [29] Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
    Olson, WC
    Rabut, GEE
    Nagashima, KA
    Tran, DNH
    Anselma, DJ
    Monard, SP
    Segal, JP
    Thompson, DAD
    Kajumo, F
    Guo, Y
    Moore, JP
    Maddon, PJ
    Dragic, T
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (05) : 4145 - 4155
  • [30] REYES G, 2001, 8 C RETR OPP INF CHI